First Mercantile Trust Co. reduced its stake in PAREXEL International Corporation (NASDAQ:PRXL) by 42.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,040 shares of the medical research company’s stock after selling 4,502 shares during the period. First Mercantile Trust Co.’s holdings in PAREXEL International Corporation were worth $525,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Arizona State Retirement System raised its position in shares of PAREXEL International Corporation by 0.9% in the second quarter. Arizona State Retirement System now owns 21,400 shares of the medical research company’s stock valued at $1,860,000 after buying an additional 200 shares during the last quarter. Boston Partners raised its position in shares of PAREXEL International Corporation by 2.4% in the second quarter. Boston Partners now owns 648,783 shares of the medical research company’s stock valued at $56,386,000 after buying an additional 15,370 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of PAREXEL International Corporation during the second quarter valued at $973,000. Global X Management Co. LLC raised its position in shares of PAREXEL International Corporation by 17.9% in the second quarter. Global X Management Co. LLC now owns 4,892 shares of the medical research company’s stock valued at $425,000 after buying an additional 742 shares during the last quarter. Finally, ARP Americas LLC purchased a new position in shares of PAREXEL International Corporation during the second quarter valued at $15,958,000. 91.58% of the stock is currently owned by institutional investors.

PAREXEL International Corporation (NASDAQ PRXL) opened at 87.67 on Tuesday. PAREXEL International Corporation has a one year low of $51.16 and a one year high of $87.86. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 38.54 and a beta of 0.79. The stock’s 50 day moving average price is $87.35 and its 200-day moving average price is $74.16.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/first-mercantile-trust-co-decreases-stake-in-parexel-international-corporation-nasdaqprxl/1489698.html.

Several brokerages have weighed in on PRXL. Zacks Investment Research raised PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 target price on the stock in a research report on Tuesday, August 8th. BidaskClub lowered PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $88.10 target price on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Barclays PLC lowered PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 target price on the stock. in a research report on Tuesday, June 20th. Finally, Raymond James Financial, Inc. raised PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $75.93.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.